SCGB1A1 has also been identified as an important bio-marker for FEV1 decline over time in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE, >3 years) [30], the Lung Health Study (>9 years) [26], and the COPDGene study (>3 years) [32]. Here, SCGB1A1 is linked to chronic obstructive pulmonary disease.